MGC Pharmaceuticals : PHARMA LAUNCHES CANNEPIL APP

7 October 2020 ASX Code: MXC

MGC Pharma launches CannEpil® App

Key Highlights:

• MGC Pharma launches CannEpil® App and provides access to the International Library of Cannabinoids to medical professionals as part of its continuing collaboration with the Royal Melbourne Institute of Technology (RMIT)
• The CannEpil® App is designed to collect patient data, whilst under the supervision of a medicinal practitioner, with the goal of further evaluating the usage, dosage and efficacy of CannEpil® as a treatment
• The International Library of Cannabinoids has been developed as a world first centralised platform compiling and curating the diverse range of existing data on the therapeutic benefits of cannabinoids
• Launch of CannEpil® App and the International Library of Cannabinoids significantly strengthens MGC Pharma's medicinal cannabis IP and allows it to remain at the forefront of cannabinoid innovation
• Data collection on this scale will provide comprehensive and transparent information on cannabinoid treatments, driving growth in the industry, facilitating higher adoption rates and allowing MXC to tailor future products and ensure their efficacy from early stages of development

MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company'), a European based bio- pharma company specialising in the production and development of phytocannabinoid-derivedmedicines, is pleased to announce it has launched the CannEpil® App ("the App"), and is providing medical professionals access to the International Library of Cannabinoids (ILC) as part of its collaboration with the Royal Melbourne Institute of Technology (RMIT).

CannEpil® App

The App is a cross platform application available to download from both the Apple App Store and Google Play Store and is intended to be used by patients (or the patient's guardian) taking CannEpil® as a prescription treatment.

The App will record patient responses to medical questionnaires as part of their treatment plan and the treating practitioner will be able to view the responses in real-time. MGC Pharma will also have access to the data on a fully anonymised basis to evaluate and report the efficacy of CannEpil®.

Links to download the App are now available

through the Company's updated website:https://mgcpharma.com.au/what-we-do/we-develop/

1

-

3

International Library of Cannabinoids (ILC)

The ILC is a world first centralised platform compiling the diverse range of existing data on the therapeutic benefits of cannabinoids. The ILC database has been designed to collect comprehensive information about clinical trials, including details of diseases and follow up treatments, as well as product identifiers, including genetics, grow conditions and chemical profile to provide doctors with an encyclopedia of exhaustive information on the best treatment for patients using cannabinoids.

The ILC has also been recognised in a paper titled Automated Gathering and Analysis of Cannabinoids Treatment Data, published in the Journal of Procedia Computer Science1, which outlines the strategic benefits of the ILC platform.

The launch of the CannEpil® App as part the development of the ILC is a strategic milestone in the Company's progress as it strengthens its medicinal cannabis IP and allows MXC to remain at the forefront of cannabinoid development with its data.

Data collection on this scale also represents a major step forward for the industry by providing transparent and comprehensive information on specific treatments, therapeutic benefits, wider implications and to advance and enhance the suites of products that are currently available to patients.

A link to login to the ILC is available to medical professionals through the Company's website: https://mgcpharma.com.au/what-we-do/we-develop/

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "Data is extremely important in the healthcare industry and is something that is not widely collected or stored at this time within the medicinal cannabis sector. The App and the ILC provides the medical community with access to what doctors need the most in order to start adopting and implementing phytocannabinoid treatments into their treatment toolkit: validated patient-baseddata, collected according to globally recognized standards, available for efficient comparative medical decision making and prescription.

The use of the data we collect in this way is designed to aid the Phytocannabinoid industry as a whole and to fill the void where there has been a significant lack of knowledge and data, responsibly collected and maintained. MXC believes this data will be invaluable for future product development, health and safety studies, and much more."

Associate Professor Nitin Mantri, RMIT University, who co-designed CannEpil® App and ILC, commented: "In this age of digital health and precision medicine, collecting patient data real-timeallows the doctors to monitor treatment and titer dosing as required. It also benefits industry to understand the various outcomes expected from the medicine and use this knowledge to further develop the products. Whilst the CannEpil® app focuses on patient outcomes for a specific formulation, ILC collects data for all different types of cannabis strains and their efficacy for treating various disorders. ILC when used by leading cannabis researchers and industries will gather evidence to demonstrate policy makers and community the various benefits of cannabis plant."

Dr. Nadya Lisovoder, Clinical Research Officer for MGC Pharma, commented: "The medical community around the world is expecting scientific based data concerning the safety and efficacy of medical cannabis-basedtreatments. In parallel with randomized clinical trials, which MGC Pharma is ahead of the curve in several indications, this active collection of medical data will support the personalization of treatments, facilitate the R&D process and encourage dialog with the medical community, which is crucial to developing viable products for the market. This data will be comprised of the demographic profile of the patients, concomitant treatments and adverse events. The efficacy data will be evaluated with tools which are validated by regulatory agencies and medical communities. We believe that this will allow MGC Pharma to base future developments on a deeper understanding of the treatments being developed, and create better products for more patients, globally."

--Ends--

1 Reference: Automated Gathering and Analysis of Cannabinoids Treatment Data

2

-

3

Authorised for release by the Board, for further information please contact:

PR/IR Advisors - Media & Capital Partners	MGC Pharmaceuticals Ltd
Melissa Hamilton (PR) [phone]	Roby Zomer
Rod Hinchcliffe (IR) [phone]	CEO & Managing Director
[e-mail]	[phone]
[e-mail]	[e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU- GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels

3

-

3